2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N2896
    Arjunolic acid 465-00-9 98.83%
    Arjunolic acid is an orally active, multifunctional bioactive compound. Arjunolic acid exhibits free radical scavenging activity, as well as fungal and bacterial activities. Arjunolic acid induces apoptosis (Apoptosis) in various cancer cells. Arjunolic acid protects hepatocytes against induced oxidative stress and apoptosis by reducing reactive oxygen species and inhibiting NF-κB activation. Arjunolic acid regulates pancreatic dysfunction in type 2 diabetic rats by blocking the activation of the TLR-4/MyD88 and canonical Wnt pathways. Arjunolic acid inhibits neuroinflammation and ameliorates depressive behaviors via the SIRT1/AMPK/Notch1 signaling pathway in microglia. Arjunolic acid improves Crohn's disease-like colitis by restoring gut microbiota composition and inhibiting TLR4 signaling. Arjunolic acid suppresses osteosarcoma progression by inhibiting Wnt3a-mediated M2 polarization of macrophages. Arjunolic acid ameliorates diabetic retinopathy via the autophagy pathway regulated by AMPK/mTOR/HO-1. Arjunolic acid is applicable to research related to type 2 diabetes, organ toxicity, depression, Crohn's disease, osteosarcoma, diabetic retinopathy, and testicular dysfunction.
    Arjunolic acid
  • HY-N2911
    Auriculasin 60297-37-2 98.58%
    Auriculasin is an anticancer agent that inhibits VEGFR2, PI3K/AKT/mTOR, MAPK. Auriculasin can inhibit cell proliferation, induce cell apoptosis, and inhibit angiogenesis, and promotes mitochondrial oxidative stress and ferroptosis. Auriculasin is also active at the cannabinoid receptor CB1 with an IC50 of 8.92 μM. Auriculasin can be used in cancer research, especially related diseases such as prostate cancer and non-small cell lung cancer, as well as research on the development of anti-angiogenic drugs.
    Auriculasin
  • HY-N3463
    Isopimaric acid 5835-26-7 99.88%
    Isopimaric acid is a potent opener of large conductance calcium activated K+ (BK) channels.
    Isopimaric acid
  • HY-N3963
    Gomisin M2 82425-45-4 99.75%
    Gomisin M2 ((+)-Gomisin M2) is a lignan isolated from the fruits of Schisandra rubriflora with anti-HIV activity (EC50 of 2.4 μM). Gomisin M2 exhibits anti-cancer and anti-allergic activities and has the potential for Alzheimer’s disease research.
    Gomisin M2
  • HY-N6577
    Astragaloside VI 84687-45-6 99.95%
    Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing.
    Astragaloside VI
  • HY-N6906
    Oleuroside 116383-31-4
    Oleuroside is a phenolic secoiridoid in olive. Oleuroside can protect against mitochondrial dysfunction in models of early Alzheimer's disease and brain ageing.
    Oleuroside
  • HY-N6908
    Continentalic acid 19889-23-7 99.72%
    Continentalic acid is a diterpenoid organic acid. Continentalic acid exhibits multiple activities including anti-inflammatory, antioxidant, neuroprotective, antibacterial and antitumor effects. Continentalic acid alleviates oxidative stress, reduces pro-inflammatory cytokine production, inhibits MAPK phosphorylation and neutrophil infiltration, and induces growth inhibition and apoptosis of cancer cells. Continentalic acid can be used in research related to traumatic brain injury, cancer, inflammation and infections.
    Continentalic acid
  • HY-N7025
    Suavissimoside R1 95645-51-5 98.71%
    Suavissimoside R1, isolated from the roots of Rubus parvifollus, possesses potent neuroprotective activity and has the potential to treat anti-Parkinson's disease agent.
    Suavissimoside R1
  • HY-N7608
    Beiwutine 76918-93-9 98.94%
    Beiwutine (10-Hydroxy mesaconitine) is a diester diterpenoid alkaloid.
    Beiwutine
  • HY-N8115
    S-(4-Hydroxybenzyl)glutathione 129636-38-0 99.92%
    S-(4-Hydroxybenzyl)glutathione is a glutathione derivative. S-(4-Hydroxybenzyl)glutathione inhibits the in vitro binding of kainic acid to brain glutamate receptors, with an IC50 of 2 μM.
    S-(4-Hydroxybenzyl)glutathione
  • HY-N8189
    Loureirin D 119425-91-1 99.30%
    Loureirin D is a dihydrochalcone found in dragon’s blood.
    Loureirin D
  • HY-N8303
    Gardenin A 21187-73-5
    Gardenin A is an orally active and synthetic PMF analogue with the neurotrophic effect for neurite outgrowth and neuronal differentiation. Gardenin A promotes neuritogenesis via activating MAPK/ERK, PKC, and PKA, but not TrkA, CREB signaling pathways. Gardenin A also has sedative, anxiolytic, antidepressant, and anticonvulsant effects.
    Gardenin A
  • HY-N9241
    3-Hydroxy-7-methoxyflavone 7478-60-6 99.39%
    3-Hydroxy-7-methoxyflavone (compound 1) is a flavonoid. 3-Hydroxy-7-methoxyflavone is isolated from natural Salvia elegans. 3-Hydroxy-7-methoxyflavone has anti-anxiety effect .
    3-Hydroxy-7-methoxyflavone
  • HY-N9404
    6-Benzoylheteratisine 99759-48-5 99.58%
    6-Benzoylheteratisine is an Aconitum alkaloid with potential neuroprotective activity. 6-Benzoylheteratisine can antagonize tetrodotoxin, inhibit the increase of [Na+]i, [Ca2+]i and glutamate release, and block sodium channels. 6-Benzoylheteratisine has an inhibitory effect on the neuronal activity underlying epileptiform burst discharge.
    6-Benzoylheteratisine
  • HY-P1046
    β-Amyloid (1-15) 183745-81-5 98.01%
    β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
    β-Amyloid (1-15)
  • HY-P1079
    ω-Agatoxin TK 158484-42-5 ≥99.0%
    ω-Agatoxin TK, a peptidyl toxin of the venom of Agelenopsis aperta, is a potent and selective P/Q type Ca2+ channel blocker. ω-Agatoxin TK inhibits the high K+ depolarisation-induced rise in internal Ca2+ in cerebral isolated nerve endings with an IC50 of of 60 nM. ω-Agatoxin TK has no effect on L-type, N-type, or T-type calcium channels.
    ω-Agatoxin TK
  • HY-P1083
    Dynamin inhibitory peptide 251634-21-6
    Dynamin inhibitory peptide competitively blocks binding of dynamin to amphiphysin, thus preventing endocytosis. Dynamin inhibitory peptide blocks the dopamine D3 effect on GABAA receptors.
    Dynamin inhibitory peptide
  • HY-P1090
    Hemopressin(rat) 568588-77-2 99.86%
    Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models.
    Hemopressin(rat)
  • HY-P1091
    Hemopressin (human, mouse) 1314035-51-2 99.95%
    Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models.
    Hemopressin (human, mouse)
  • HY-P1095
    Ivachtin 745046-84-8 ≥99.0%
    Ivachtin (Caspase-3 Inhibitor VII; compound 7a) is a nonpeptide, noncompetitive and reversibl caspase-3 inhibitor with an IC50 of 23 nM. Ivachtin has modest selectivity for the remaining caspases.
    Ivachtin
Cat. No. Product Name / Synonyms Application Reactivity